McLaughlin Asset Management Inc. Has $1.16 Million Stock Position in Boston Scientific Corporation $BSX

McLaughlin Asset Management Inc. grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 198.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,458 shares of the medical equipment provider’s stock after buying an additional 12,272 shares during the quarter. Boston Scientific makes up 1.1% of McLaughlin Asset Management Inc.’s holdings, making the stock its 29th biggest holding. McLaughlin Asset Management Inc.’s holdings in Boston Scientific were worth $1,158,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of BSX. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the fourth quarter worth about $26,000. Bangor Savings Bank grew its holdings in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares during the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 9,800 shares of company stock worth $554,012 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on BSX shares. Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a research report on Thursday, May 28th. Jefferies Financial Group dropped their price target on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, UBS Group decreased their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $82.12.

Boston Scientific Stock Up 1.6%

Shares of NYSE:BSX opened at $45.30 on Wednesday. The company has a market capitalization of $67.33 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 0.85 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The business’s 50-day moving average is $50.23 and its 200-day moving average is $68.58. Boston Scientific Corporation has a 1 year low of $42.25 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.